Healthcare provider profile · identity verified

David L Gullett, M.D.

Internal Medicine · CLARKSVILLE, TN · NPI 1568481125

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	704	195
Amlodipine Besylate	Amlodipine Besylate	461	140
Lisinopril	Lisinopril	366	98
Omeprazole	Omeprazole	338	95
Losartan Potassium	Losartan Potassium	322	101
Levothyroxine Sodium	Levothyroxine Sodium	268	73
Gabapentin	Gabapentin	199	46
Metoprolol Tartrate	Metoprolol Tartrate	181	50
Albuterol Sulfate Hfa	Albuterol Sulfate	179	56
Clopidogrel	Clopidogrel Bisulfate	155	41
Metformin Hcl	Metformin Hcl	146	47
Hydrochlorothiazide	Hydrochlorothiazide	143	49
Pantoprazole Sodium	Pantoprazole Sodium	121	35
Furosemide	Furosemide	119	36
Simvastatin	Simvastatin	117	28
Carvedilol	Carvedilol	109	34
Montelukast Sodium	Montelukast Sodium	106	30
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	103	36
Tramadol Hcl	Tramadol Hcl	101	22
Fluticasone Propionate	Fluticasone Propionate	100	34
Metoprolol Succinate	Metoprolol Succinate	100	30
Potassium Chloride	Potassium Chloride	96	33
Alprazolam	Alprazolam	91	13
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	88	25
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	88	39
Eliquis	Apixaban	84	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	83	23
Tamsulosin Hcl	Tamsulosin Hcl	80	26
Metformin Hcl Er	Metformin Hcl	76	27
Alendronate Sodium	Alendronate Sodium	74	20
Glipizide Er	Glipizide	74	23
Rosuvastatin Calcium	Rosuvastatin Calcium	72	27
Nifedipine Er	Nifedipine	70	12
Trazodone Hcl	Trazodone Hcl	70	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	64	17
Meloxicam	Meloxicam	64	21
Lorazepam	Lorazepam	62	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	60	26
Glipizide	Glipizide	56	17
Chlorthalidone	Chlorthalidone	54	17
Diazepam	Diazepam	52	suppressed
Famotidine	Famotidine	50	15
Levetiracetam	Levetiracetam	45	suppressed
Ozempic	Semaglutide	45	suppressed
Azithromycin	Azithromycin	43	37
Clonazepam	Clonazepam	42	suppressed
Pravastatin Sodium	Pravastatin Sodium	41	15
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	41	suppressed
Ventolin Hfa	Albuterol Sulfate	41	suppressed
Atenolol	Atenolol	39	11
Sertraline Hcl	Sertraline Hcl	38	12
Farxiga	Dapagliflozin Propanediol	37	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	37	suppressed
Allopurinol	Allopurinol	36	11
Buspirone Hcl	Buspirone Hcl	36	12
Ibuprofen	Ibuprofen	36	15
Hydralazine Hcl	Hydralazine Hcl	33	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	30	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Pregabalin	Pregabalin	30	suppressed
Spironolactone	Spironolactone	30	suppressed
Tresiba Flextouch U-200	Insulin Degludec	30	suppressed
Xarelto	Rivaroxaban	30	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	30	suppressed
Ezetimibe	Ezetimibe	29	suppressed
Indapamide	Indapamide	28	suppressed
Benazepril Hcl	Benazepril Hcl	26	suppressed
Ondansetron Odt	Ondansetron	26	12
Trulicity	Dulaglutide	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Gemtesa	Vibegron	23	suppressed
Synthroid	Levothyroxine Sodium	23	suppressed
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Ropinirole Hcl	Ropinirole Hcl	22	suppressed
Arnuity Ellipta	Fluticasone Furoate	21	suppressed
Celecoxib	Celecoxib	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	21	suppressed
Rybelsus	Semaglutide	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Baclofen	Baclofen	20	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	20	suppressed
Prednisone	Prednisone	20	13
Dilt-Xr	Diltiazem Hcl	19	suppressed
Humalog Kwikpen U-100	Insulin Lispro	19	suppressed
Myrbetriq	Mirabegron	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	18	suppressed
Jardiance	Empagliflozin	18	suppressed
Spiriva Respimat	Tiotropium Bromide	18	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	18	suppressed
Verapamil Er	Verapamil Hcl	18	suppressed
Acyclovir	Acyclovir	17	suppressed
Cephalexin	Cephalexin	17	13
Diltiazem 24hr Er	Diltiazem Hcl	17	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	17	suppressed
Primidone	Primidone	17	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Estradiol	Estradiol	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	14	suppressed
Nystatin	Nystatin	14	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	13	suppressed
Telmisartan	Telmisartan	13	suppressed
Estarylla	Norgestimate-Ethinyl Estradiol	12	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	12	suppressed
Finasteride	Finasteride	12	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Diltiazem 12hr Er	Diltiazem Hcl	11	suppressed
Methylprednisolone	Methylprednisolone	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error